PMID- 195661
OWN - NLM
STAT- MEDLINE
DCOM- 19770917
LR  - 20181113
IS  - 0007-1188 (Print)
IS  - 0007-1188 (Linking)
VI  - 60
IP  - 2
DP  - 1977 Jun
TI  - The role of beta-adrenoceptors in the responses of the hepatic arterial vascular 
      bed of the dog to phenylephrine, isoprenaline, noradrenaline and adrenaline.
PG  - 239-49
AB  - 1 The sympathetically-innervated hepatic arterial vascular bed of the dog was 
      perfused from a femoral artery. Hepatic arterial blood flow and perfusion 
      pressure were recorded continuously, and the hepatic arterial vascular resistance 
      (HAVR) calculated from these measurements.2 Intra-arterial injections of 
      phenylephrine caused dose-dependent rises in HAVR, indicating hepatic arterial 
      vasoconstriction, at all doses above threshold. No secondary reductions in HAVR 
      followed these responses.3 Intra-arterial injections of isoprenaline caused only 
      dose-dependent reductions in HAVR at doses above threshold.4 Intra-arterial 
      injections of noradrenaline typically caused an initial increase in HAVR which 
      was followed at all but the highest doses by a secondary, delayed, reduction in 
      HAVR.5 Intra-arterial injections of adrenaline, like those of noradrenaline, 
      resulted in hepatic arterial vasoconstriction followed by hepatic arterial 
      vasodilatation.6 On a molar basis, the most potent hepatic arterial 
      vasoconstrictor was noradrenaline, followed by adrenaline and phenylephrine.7 The 
      maximum reductions in HAVR caused by adrenaline (mean reduction = 21.9%) and 
      noradrenaline (16.9%) were significantly smaller than those due to isoprenaline 
      ((P) < 0.001).8 Propranolol attenuated the hepatic arterial vasodilator responses 
      due to isoprenaline, and the secondary falls in HAVR following intra-arterial 
      adrenaline and noradrenaline.9 Propranolol did not modify the vasoconstrictor 
      responses to phenylephrine.10 Both adrenaline and noradrenaline were more potent 
      hepatic arterial vasoconstrictors after propranolol than in the absence of 
      beta-adrenoceptor blockade. The potentiation of the vasoconstrictor effects of 
      adrenaline was statistically significant.11 After propranolol, adrenaline was a 
      more potent hepatic arterial vasoconstrictor than noradrenaline.12 Since the 
      beta-adrenoceptors in the hepatic arterial vasculature were not blocked by 
      atenolol, but were stimulated by salbutamol, it is concluded that they are 
      predominantly of the beta(2)-type.13 The vasoconstrictor actions of 
      phenylephrine, noradrenaline and adrenaline were all antagonized by the systemic 
      administration of phentolamine, all three dose-response curves being shifted to 
      the right.14 The results are discussed with regard to the possible control of the 
      hepatic arterial vasculature by naturally-occurring catecholamines.
FAU - Richardson, P D
AU  - Richardson PD
FAU - Withrington, P G
AU  - Withrington PG
LA  - eng
PT  - Journal Article
PL  - England
TA  - Br J Pharmacol
JT  - British journal of pharmacology
JID - 7502536
RN  - 0 (Receptors, Adrenergic)
RN  - 0 (Receptors, Adrenergic, beta)
RN  - 1WS297W6MV (Phenylephrine)
RN  - 50VV3VW0TI (Atenolol)
RN  - 9Y8NXQ24VQ (Propranolol)
RN  - L628TT009W (Isoproterenol)
RN  - QF8SVZ843E (Albuterol)
RN  - X4W3ENH1CV (Norepinephrine)
RN  - YKH834O4BH (Epinephrine)
SB  - IM
MH  - Albuterol/pharmacology
MH  - Animals
MH  - Atenolol/pharmacology
MH  - Dogs
MH  - Dose-Response Relationship, Drug
MH  - Drug Interactions
MH  - Epinephrine/*pharmacology
MH  - Hepatic Artery/innervation
MH  - Isoproterenol/*pharmacology
MH  - Liver Circulation/*drug effects
MH  - Norepinephrine/*pharmacology
MH  - Phenylephrine/*pharmacology
MH  - Propranolol/pharmacology
MH  - Receptors, Adrenergic/*physiology
MH  - Receptors, Adrenergic, beta/drug effects/*physiology
MH  - Vascular Resistance/drug effects
PMC - PMC1667473
EDAT- 1977/06/01 00:00
MHDA- 1977/06/01 00:01
PMCR- 1978/06/01
CRDT- 1977/06/01 00:00
PHST- 1977/06/01 00:00 [pubmed]
PHST- 1977/06/01 00:01 [medline]
PHST- 1977/06/01 00:00 [entrez]
PHST- 1978/06/01 00:00 [pmc-release]
PST - ppublish
SO  - Br J Pharmacol. 1977 Jun;60(2):239-49.